SELLAS CFO awarded 300,000 restricted stock units

SELLAS Life Sciences Group, Inc. reported that its CFO, John Thomas Burns, received an award of 300,000 restricted stock units of common stock on January 7, 2026.

Rhea-AI Filing Summary

SELLAS Life Sciences Group, Inc. reported that its CFO, John Thomas Burns, received an award of 300,000 restricted stock units of common stock on January 7, 2026. The Form 4 shows this as an acquisition at a price of $0.00 per share, reflecting an equity compensation grant rather than an open‑market purchase.

The RSUs are scheduled to vest over four years: 25% on December 1, 2026 and 25% on each December 1 thereafter, as long as he remains in service with the company through each vesting date. After this grant, Burns is reported to beneficially own 554,327 shares of common stock, held directly.

Insider Trade Summary

Grant/Award: 300,000 shares

Grant/Award 1 txn

Insider Burns John Thomas

Role CFO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	300,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 554,327 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did SELLAS (SLS) report in this Form 4?

The company reported that CFO John Thomas Burns received an award of 300,000 restricted stock units of SELLAS common stock on January 7, 2026.

At what price were the SELLAS (SLS) RSUs granted to the CFO?

The Form 4 lists the acquisition of 300,000 shares of common stock at a price of $0.00 per share, indicating a compensatory RSU grant.

How do the 300,000 RSUs granted to the SELLAS CFO vest?

The 300,000 RSUs vest as follows: 25% on December 1, 2026 and 25% on each December 1 thereafter until fully vested, if he remains in service with SELLAS through each vesting date.

How many SELLAS (SLS) shares does the CFO beneficially own after this RSU grant?

Following the reported transaction, CFO John Thomas Burns is shown as beneficially owning 554,327 shares of SELLAS common stock, held directly.

Is the SELLAS CFO considered a 10% owner in this Form 4?

No. The filing identifies John Thomas Burns as an officer (CFO) of SELLAS Life Sciences Group, Inc., and does not mark him as a 10% owner.

Does this Form 4 indicate indirect ownership or entities holding shares for the SELLAS CFO?

No. The reported 554,327 shares following the transaction are classified as Direct (D) ownership, with no nature of indirect beneficial ownership noted.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/09/2026 - 04:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burns John Thomas

(Last) (First) (Middle)

C/O SELLAS LIFE SCIENCES GROUP, INC.,

7 TIMES SQUARE, SUITE 2503

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SELLAS Life Sciences Group, Inc. [ SLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/07/2026		A		300,000(1)	A	$0.00	554,327	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person received an award of 300,000 restricted stock units on January 7, 2026, which shall vest as follows: (i) 25% on December 1, 2026 and (ii) 25% on each December 1 thereafter until fully vested, provided that the Reporting Person remains in service with the Issuer through each such vesting date.

	/s/ Daniel Bagliebter, Power of Attorney For: John Burns	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.